Lv43
620 积分 2023-03-16 加入
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
18天前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
21天前
已完结
Target Occupancy Biomarker Assay Development Using a Conformation-Selective Antibody Against Small-Molecule-Bound TNF
28天前
已完结
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond
28天前
已完结
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond
1个月前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
1个月前
已完结
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
1个月前
已完结
Autoimmune haemolytic anaemias
1个月前
已完结
Canonical and non-canonical roles of complement in atherosclerosis
1个月前
已完结
Complosome — the intracellular complement system
1个月前
已完结
皖公网安备34019202002308
